Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant.Genotype to Phenotype Japan (G2P‐Japan) ConsortiumTsujino S., Deguchi S., Nomai T., Padilla-Blanco M., Plianchaisuk A., Wang L., Begum M.M., Uriu K., Mizuma K.[...], Sato K.View abstractCategoriesStructureSourcePDB: 8WMD, PDB: 8WMF, PDB: 8XLM, PDB: 8XLNPubMedEurope PMCMicrobiol Immunol 68:305-330 (2024)Mapped to2
A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation.Yang Y., Zhang J., Zhang S., Zhang C., Shen C., Song S., Wang Y., Peng Y., Gong X.[...], Lu H.View abstractCategoriesStructureSourcePDB: 8JYSPubMedEurope PMCExploration (Beijing) 4:20230086-20230086 (2024)Mapped to1
The binding and structural basis of fox ACE2 to RBDs from different sarbecoviruses.Chen J., Sun J., Xu Z., Li L., Kang X., Luo C., Wang Q., Guo X., Li Y.[...], Wu Y.View abstractCategoriesStructureSourcePDB: 8XZDPubMedEurope PMCVirol Sin 39:609-618 (2024)Mapped to1
The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.Chen X., Mohapatra A., Nguyen H.T.V., Schimanski L., Kit Tan T., Rijal P., Chen C.P., Cheng S.H., Lee W.H.[...], Huang K.A.View abstractCategoriesStructureSourcePDB: 8X0X, PDB: 8X0Y, PDB: 8YRO, PDB: 8YRP, PDB: 8YZ5PubMedEurope PMCPLoS Pathog 20:e1012246-e1012246 (2024)Mapped to1
Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes.Hurtado J., Rogers T.F., Jaffe D.B., Adams B.A., Bangaru S., Garcia E., Capozzola T., Messmer T., Sharma P.[...], Briney B.View abstractCategoriesStructureSourcePDB: 8SWHPubMedEurope PMCCell Rep 43:114307-114307 (2024)Mapped to1
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.Cornish K., Huo J., Jones L., Sharma P., Thrush J.W., Abdelkarim S., Kipar A., Ramadurai S., Weckener M.[...], Owens R.J.View abstractCategoriesStructureSourcePDB: 8OWT, PDB: 8OWV, PDB: 8OWW, PDB: 8OYUPubMedEurope PMCOpen Biol 14:230252-230252 (2024)Mapped to3
An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike.Liu B., Niu X., Deng Y., Zhang Z., Wang Y., Gao X., Liang H., Li Z., Wang Q.[...], Xiong X.View abstractCategoriesStructureSourcePDB: 8ZBZ, PDB: 8ZC0, PDB: 8ZC1, PDB: 8ZC2, PDB: 8ZC3, PDB: 8ZC4, PDB: 8ZC5, PDB: 8ZC6PubMedEurope PMCCell Rep 43:114265-114265 (2024)Mapped to1
Functional and structural investigation of a broadly neutralizing SARS- CoV-2 antibody.Chang Y.H., Hsu M.F., Chen W.N., Wu M.H., Kong W.L., Lu M.J., Huang C.H., Chang F.J., Chang L.Y.[...], Lin K.I.View abstractCategoriesStructureSourcePDB: 8XBFPubMedEurope PMCJCI Insight 9:e179726-e179726 (2024)Mapped to1
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity- matured public antibodies.Sheward D.J., Pushparaj P., Das H., Greaney A.J., Kim C., Kim S., Hanke L., Hyllner E., Dyrdak R.[...], Hallberg B.M.View abstractCategoriesStructureSourcePDB: 8C0Y, PDB: 8V4FPubMedEurope PMCCell Rep Med 5:101577-101577 (2024)Mapped to1
Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses.Liu C., Xu S., Zheng Y., Xie Y., Xu K., Chai Y., Luo T., Dai L., Gao G.F.View abstractCategoriesStructureSourcePDB: 8XXWPubMedEurope PMCCell Rep 43:114235-114235 (2024)Mapped to2
The impact of SARS-CoV-2 spike mutation on peptide presentation is HLA allomorph-specific.Ahn Y.M., Maddumage J.C., Grant E.J., Chatzileontiadou D.S.M., Perera W.W.J.G., Baker B.M., Szeto C., Gras S.View abstractCategoriesStructureSourcePDB: 8RBU, PDB: 8RCV, PDB: 8REF, PDB: 8RH6, PDB: 8RHQPubMedEurope PMCCurr Res Struct Biol 7:100148-100148 (2024)Cited in4Mapped to2
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.OPTIC ConsortiumLiu C., Zhou D., Dijokaite-Guraliuc A., Supasa P., Duyvesteyn H.M.E., Ginn H.M., Selvaraj M., Mentzer A.J., Das R.[...], Screaton G.R.View abstractCategoriesStructureSourcePDB: 8QRF, PDB: 8QRG, PDB: 8QSQ, PDB: 8QTD, PDB: 8R80PubMedEurope PMCCell Rep Med 5:101553-101553 (2024)Cited in1Mapped to3
Computationally restoring the potency of a clinical antibody against Omicron.Tri-lab COVID-19 ConsortiumDesautels T.A., Arrildt K.T., Zemla A.T., Lau E.Y., Zhu F., Ricci D., Cronin S., Zost S.J., Binshtein E.[...], Zhang B.View abstractCategoriesStructureSourcePDB: 8EKDPubMedEurope PMCNature 629:878-885 (2024)Mapped to1
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.Liu C., Das R., Dijokaite-Guraliuc A., Zhou D., Mentzer A.J., Supasa P., Selvaraj M., Duyvesteyn H.M.E., Ritter T.G.[...], Screaton G.R.View abstractCategoriesStructureSourcePDB: 8CBD, PDB: 8CBE, PDB: 8CBF, PDB: 8CMA, PDB: 8QZRPubMedEurope PMCNat Commun 15:3284-3284 (2024)Mapped to1
Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.Ishimaru H., Nishimura M., Shigematsu H., Marini M.I., Hasegawa N., Takamiya R., Iwata S., Mori Y.View abstractCategoriesStructureSourcePDB: 8XI6PubMedEurope PMCJ Virol 98:e0041624-e0041624 (2024)Mapped to1
Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.Yang R., Han P., Han P., Li D., Zhao R., Niu S., Liu K., Li S., Tian W.-X., Gao G.F.View abstractCategoriesStructureSourcePDB: 8WLO, PDB: 8WLRPubMedEurope PMCJ Virol 98:e0045124-e0045124 (2024)Cited in1Mapped to1
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.Zhou D., Supasa P., Liu C., Dijokaite-Guraliuc A., Duyvesteyn H.M.E., Selvaraj M., Mentzer A.J., Das R., Dejnirattisai W.[...], Screaton G.R.View abstractCategoriesStructureSourcePDB: 8CIN, PDB: 8R1C, PDB: 8R1DPubMedEurope PMCNat Commun 15:2734-2734 (2024)Mapped to2
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.Magaret C.A., Li L., deCamp A.C., Rolland M., Juraska M., Williamson B.D., Ludwig J., Molitor C., Benkeser D.[...], Gilbert P.B.View abstractCategoriesStructureSourcePDB: 8VYE, PDB: 8VYF, PDB: 8VYGPubMedEurope PMCNat Commun 15:2175-2175 (2024)Mapped to1
The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis.He X., Zhang X., Wu B., Deng J., Zhang Y., Zhu A., Yuan Y., Lin Y., Chen A.[...], Zhang H.View abstractCategoriesStructureSourcePDB: 8WGV, PDB: 8WGWPubMedEurope PMCNat Immunol 25:622-632 (2024)Mapped to5
A general computational design strategy for stabilizing viral class I fusion proteins.Gonzalez K.J., Huang J., Criado M.F., Banerjee A., Tompkins S.M., Mousa J.J., Strauch E.M.View abstractCategoriesStructureSourcePDB: 8FEZPubMedEurope PMCNat Commun 15:1335-1335 (2024)Mapped to4
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.de Campos-Mata L., Trinite B., Modrego A., Tejedor Vaquero S., Pradenas E., Pons-Grifols A., Rodrigo Melero N., Carlero D., Marfil S.[...], Magri G.View abstractCategoriesStructureSourcePDB: 8C89PubMedEurope PMCNat Commun 15:1051-1051 (2024)Mapped to1
Structural basis and analysis of hamster ACE2 binding to different SARS- CoV-2 spike RBDs.Niu S., Zhao Z., Liu Z., Rong X., Chai Y., Bai B., Han P., Shang G., Ren J.[...], Gao G.F.View abstractCategoriesStructureSourcePDB: 8KA8, PDB: 8KC2PubMedEurope PMCJ Virol 98:e0115723-e0115723 (2024)Cited in1Mapped to1
Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.Wang Y., Yan A., Song D., Duan M., Dong C., Chen J., Jiang Z., Gao Y., Rao M.[...], Zhao J.View abstractCategoriesStructureSourcePDB: 8H7L, PDB: 8H7ZPubMedEurope PMCNat Commun 15:842-842 (2024)Mapped to1
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2.Bruch E.M., Zhu S., Szymkowicz L., Blake T., Kiss T., James D.A., Rak A., Narayan K., Balmer M.T., Chicz R.M.View abstractCategoriesStructureSourcePDB: 8TYL, PDB: 8TYOPubMedEurope PMCSci Rep 14:2038-2038 (2024)Mapped to1
Integrating artificial intelligence-based epitope prediction in a SARS- CoV-2 antibody discovery pipeline: caution is warranted.Acar D.D., Witkowski W., Wejda M., Wei R., Desmet T., Schepens B., De Cae S., Sedeyn K., Eeckhaut H.[...], Vandekerckhove L.View abstractCategoriesStructureSourcePDB: 8QPRPubMedEurope PMCEBioMedicine 100:104960-104960 (2024)Mapped to2